



28 April 2020

ASX Announcement

Penthrox is approved in Thailand

Medical Developments International Limited (ASX: MVP), announce today that Penthrox® has been granted Market Authorisation in the Kingdom of Thailand. The Marketing Authorisation issued by the Thailand Food and Drug Administration (TFDA), is for Penthrox® to be used for Emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.

Chairman David Williams said: "This is an important approval as Thailand is a key market for Penthrox throughout the Asian Region. It is the first approval we have obtained with our partners Daiichi Sankyo who are also our partners in China and Vietnam. We expect the granting of this Marketing Authorisation will have positive ramifications for the rest of this region and we hope this approval is a catalyst for a number of other country approvals in Asia."

Authorised for release by MVP Chairman, David Williams.

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 (0) 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 (3) 9547 1888



About Pentrox®

PENTHROX® (methoxyflurane) is the only small, lightweight, handheld, fast-acting, inhaled analgesic that is self-administered under the supervision of the treating healthcare practitioner, indicated for the short-term relief of moderate to severe pain, associated with trauma or interventional medical procedures, in conscious adult patients. Pentrox® provides rapid, effective pain relief in 5 minutes, with no need for needles and is not classified as an opioid. Pentrox® allows patients to control their own pain relief by moderating the amount of Pentrox® inhaled¹.

About Medical Developments International Ltd

MDI is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MDI is a leader in emergency pain relief and respiratory products. The Company manufactures Pentrox®, a fast-acting trauma & pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defense Forces, sports medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MDI is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.